1416799-28-4
1416799-28-4
Chemical Structure
AMG 333
- CAS No.: 1416799-28-4
- Formula:C20H12F5N3O4
- Molecular Weight:453.32
IUPAC Name: (S)-6-(((3-fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic acid
InChIKey: QEBYISWYMFIXOZ-INIZCTEOSA-N
SMILES: FC1=CC=CN=C1[C@H](C2=CC(F)=C(OC(F)(F)F)C=C2)NC(C3=NC=C(C(O)=O)C=C3)=O
Biological Activity: AMG 333 is an orally active and highly selective TRPM8 antagonist with an IC50 of 13 nM.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AMG 333 | 99.83% | AMG 333 is an orally active and highly selective TRPM8 antagonist with an IC50 of 13 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AVE5688 | 98.79% | AVE5688 is an inhibitor of glycogen phosphorylase (GP), with IC50s of 430 nM and 915 nM and Kds of 170 nM and 530 nM for rabbit muscle glycogen phosphorylase (rmGPb and rmGPa, respectively); AVE5688 can be used for the research of type 2 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Regorafenib monohydrate (Standard) | ≥98% | Regorafenib (monohydrate) (Standard) is the analytical standard of Regorafenib (monohydrate). This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Regorafenib (Standard) | ≥98% | Regorafenib (Standard) is the analytical standard of Regorafenib. This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Regorafenib Hydrochloride | 99.09% | Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AHR antagonist 2 | 99.30% | AHR antagonist 2 (Example 1) is a potent aryl hydrocarbon receptor (AHR) antagonist with IC50s of 885 pM and 2.03 nM for human and mouse AHR. AHR antagonist 2 can be used for the studies of cancers and imbalance of the immune response. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BCH001 | 98.72% | BCH001, a quinoline derivative, is a specific PAPD5 inhibitor. BCH001 restores telomerase activity and telomere length in dyskeratosis congenita (DC) induced pluripotent stem cells. BCH001 shows no inhibition of poly(A)-specific ribonuclease (PARN) or several other canonical and non-canonical polynucleotide polymerases. BCH001 is used to regulate aging. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
IMP2-IN-1 | 99.55% | IMP2-IN-1 (compound 4) is a potent IMP2 inhibitor with IC50 value of 81.3~127.5 for IMP2 RNA sequence. IMP2-IN-1 reduces IMP2 in SW480 cells. IMP2-IN-1 significantly reduces the viability of both differentiated and non-differentiated Huh7 cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Aurora kinase-IN-3 | 99.02% | Aurora kinase-IN-3 (Compound 15a) is an orally active AURKB inhibitor that elicits an AURKB-suppressive activity by disrupting the mitotic localization of AURKB, rather than inhibiting its phosphorylation of H3 at Ser10. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ONO-2920632 | 99.11% | ONO-2920632 is an orally active and central nervous system (CNS)-penetrant TREK activator, with EC50 values of 0.3 µM and 2.8 μM for TREK-1 and TREK-2, respectively. ONO-2920632 exhibits selectivity for other K2P channels (>91-fold selective versus TASK1, TASK2, TASK3, TRAAK, and TWIK2; 31-fold selective versus TRESK). ONO-2920632 possesses analgesic effects and can be used in research on pain, migraine, and neurological disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Regorafenib impurity 1 | 99.73% | Regorafenib Impurity 45 is an impurity of Regorafenib (HY-10331). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
